SingleInvestigationalEarly HumanLow confidenceSourced

Ipamorelin

A ghrelin-receptor agonist with early human pharmacology and an intravenous phase 2 postoperative study. Neither establishes a routine subcutaneous wellness protocol.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Community-reported schedule

Community-reported · not a validated schedule

Community dose schedule

A community-provenance subcutaneous pattern from authenticated forum archives - roughly 200-300 mcg daily, usually paired with a GHRH. Community reports only, not a validated or trial-verified schedule.

Evidence source

Reported maximum quantityChoose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.

Reported quantities by phase

Select a point for its calculation examples

Daily (often 5 on / 2 off)
250 mcg
Reports cluster at 200-300 mcg daily, often split morning and evening and paired with a GHRH; some read 200-300 mcg as a per-dose amount.

Vial-aware arithmetic

Reconstitution examples, up to 3 mL

Choose the vial quantity and BAC water first. The diagram and results below update for the selected 250 mcg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.

Vial quantity

Choose the quantity printed on the vial.

BAC water added

Use 1, 2 or 3 mL, or enter a custom volume up to 3 mL.

Open the full reverse calculator

Three millilitre research vial, diluent vial and capped U-100 syringe on an ink-blue surface — One small vial, one measured diluent volume and one U-100 scale. The arithmetic connects all three.

BAC water selected

3 mL

Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.

U-100 draw15 U

20-30 U reference band

1 mL BAC

5 units

resulting U-100 draw

Concentration: 5 mg/mL
BAC added: 1 mL

2 mL BAC

10 units

resulting U-100 draw

Concentration: 2.5 mg/mL
BAC added: 2 mL

3 mL BAC

15 units

resulting U-100 draw

Concentration: 1.667 mg/mL
BAC added: 3 mL

Shown in the diagram. Closest of these examples to 25 units.

Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Human StudyIntravenous infusionTwice daily through day 7 or discharge

Adults after bowel resection in a phase 2 hospital trial

0.03 mg/kg by intravenous infusion twice daily from postoperative day 1 through day 7 or discharge

This was an inpatient postoperative ileus study and did not establish subcutaneous or long-term use.

View source

Human StudyIntravenous infusionSingle monitored exposure

Healthy male volunteers

Single 15-minute intravenous infusions across five dose-escalation cohorts

This pharmacology experiment measured short-term growth-hormone release rather than a clinical outcome.

View source

Community GuideSubcutaneous in reportsDaily, often divided; cycle disputed

online research community summaries and reports

The spotlight states 200-300 mcg subcutaneously per day, often split into two or three administrations for 8-12 weeks followed by four weeks off

Other posts interpret 200-300 mcg as a per-administration amount and an expert says cycling may not be necessary. The archive therefore contains a material total-daily-versus-per-dose ambiguity; raw/peptide-education/pe-ipamorelin.md:25-27 and 80-116.

View source

Community GuideSubcutaneous in reportsDaily, often five on and two off

authenticated research-forum (Peppys) ipamorelin reports and reference charts

Subcutaneous reports cluster around 200-300 mcg daily, commonly split into a morning and evening dose and paired with a GHRH such as tesamorelin or CJC-1295 no-DAC; many run five days on and two off in roughly eight-week cycles, and reference charts list 200 mcg five days a week or 300 mcg daily

Forum provenance from an authenticated archive with usernames omitted. Ipamorelin is the GHRP half of the pairing and is kept separate from the GHRH it is combined with; reports conflict over whether 200-300 mcg is a total-daily or per-administration amount, and the archive states human dosing is not established.

View source

Evidence summary

A ghrelin-receptor agonist with early human pharmacology and an intravenous phase 2 postoperative study. Neither establishes a routine subcutaneous wellness protocol.

Protocol basis

The page reports the actual intravenous study designs and makes the route mismatch visible instead of translating them into subcutaneous units.

Community provenance (Peppys)

An authenticated research-forum archive records subcutaneous ipamorelin clustering around 200-300 mcg daily, frequently divided between morning and evening and almost always paired with a growth-hormone-releasing hormone such as tesamorelin or CJC-1295 no-DAC. Reports conflict over whether 200-300 mcg is a total daily amount or a per-administration dose, and cadence ranges from continuous use to eight-week blocks dosed five days on and two off. Usernames and post numbers are omitted and the quantities are logged as community provenance without endorsement. The planner above reproduces the arithmetic of these reported quantities; it does not validate them.

What remains uncertain

A validated outpatient indication, subcutaneous exposure, long-term safety and clinical benefit are not established.

Warnings and contraindications

The best clinical outcome trial used intravenous infusions in hospital patients.

Growth-hormone responses do not prove meaningful clinical benefit.

A subcutaneous research vial does not match the studied intravenous formulation.

Organised research bench with labelled storage tray, vial rack, notebook and thermometer — A clean workspace supports traceability. It does not establish sterility.

Shared across protocols

Supplies and general handling

Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.

Research vial

Select the labelled vial quantity used in the calculation.

View Peppys vial

Bacteriostatic water

Use only a diluent appropriate to the research method and formulation.

View Peppys BAC water

U-100 measuring syringe

Use a new sterile device for every entry. Source locally.

Source locally

Wipes and sharps container

Plan clean handling and immediate sharps disposal. Source locally.

Source locally

Storage follows the label

Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.

Use sterile equipment once

CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.

Stability is formulation-specific

Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.

General references: CDC injection safety, NHS medicine storage and DailyMed BAC water labelling.